Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | GMMG-DANTE: DVd in patients with multiple myeloma and renal impairment

Lisa Leypoldt • 29 Sep 2023
IMS 2023
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone
GMMG-DANTE

Lisa Leypoldt, MD, University Medical Center Hamburg, Hamburg, Germany, briefly discusses the Phase II GMMG-DANTE trial (NCT02977494), which investigated the combination of daratumumab, bortezomib and dexamethasone (DVd) in patients with multiple myeloma and renal impairment. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Advisory role/honoraria: GSK, Sanofi, Janssen, Bristol Myers Squibb/Celgene
Research support: AbbVie, GSK (both to the institution)
Travel support: Sanofi
Other (travel support, training): GSK, Sanofi, AbbVie

More from Lisa Leypoldt

1:50
Clinical trials exploring treatment approaches for high-risk NDMM
Lisa Leypoldt • 29 Sep 2023
2:08
GMMG-CONCEPT trial: Isa-KRd in high-risk newly diagnosed multiple myeloma
Lisa Leypoldt • 29 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals